Immune cells may predict CMV relapse in kidney transplant patients
NCT ID NCT03339661
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 38 kidney transplant patients who had CMV infection. Researchers wanted to see if measuring a type of immune cell (γδ T cells) could help decide who needs extra medication to prevent the virus from coming back. The goal is to avoid unnecessary drugs while still protecting the transplanted kidney.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Edouard Herriot - Hospices Civils de Lyon
Lyon, 69003, France
-
Hôpital Pellegrin - CHU de Bordeaux
Bordeaux, 33000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Transplant breakdown? new study checks organ fluid for hidden germs
- Kidney transplant patients' immune response to common virus tracked after drug switch
- Harmless virus levels may predict transplant complications
- Kidney transplant virus filter trial pulled before start
- New blood test may help protect kids from post-transplant infection
- Can a simple infusion save transplanted kidneys from a stealthy virus?